Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized 4 Week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Moderate to Severe Pain Due to Osteoarthritis (OA) of the Knee

NCT01357837 is registered in ClinicalTrials.gov with Tris Pharma, Inc. as lead sponsor.

NCT NCT01357837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01357837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized 4 Week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Moderate to Severe Pain Due to Osteoarthritis (OA) of the Knee
Lead sponsor
Tris Pharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2011
Completion date
December 31, 2011
Enrollment
207 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis of the knee